October 2022 - Volume 81 - 10

HEROES AND PILLARS OF RHEUMATOLOGY

1. EULAR 75-year anniversary: commentaries on ARD papers from 50 years ago

VIEWPOINT

2. Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake

EDUCATION

3. Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countriesEditor's Choice

RHEUMATOID ARTHRITIS

4. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration (15 June, 2022)

5. Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring

6. Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis

7. Standardisation of ACPA tests: evaluation of a new candidate reference preparation

8. Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response

PSORIATIC ARTHRITIS

9. Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial

10. Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease

SYSTEMIC LUPUS ERYTHEMATOSUS

11. Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis

12. Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

13. Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature

VASCULITIS

14. The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study (13 June, 2022)

AUTOIMMUNITY

15. Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study

AUTOINFLAMMATORY DISORDERS

16. Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome

OSTEOARTHRITIS

17. NOD/RIPK2 signalling pathway contributes to osteoarthritis susceptibility

IMAGES IN RHEUMATOLOGY

18. Livedo racemosa and thrombotic vasculitides of scalp in systemic lupus erythematosus

LETTERS

19. Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination

20. Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series

21. Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis

22. Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica

ELECTRONIC PAGES

23. Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience

24. Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al

25. COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs

26. COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al

27. Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future

28. Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al

29. Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al

30. Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley

31. Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study’ by Della-Torre et al

32. Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang

33. Colchicine treatment in community healthcare setting to prevent severe COVID-19

34. Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al

35. Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic

36. Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al

37. High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab

38. Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al

39. Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimar et al

40. Response to: ‘Tofacitinib for the treatment of polyarteritis nodosa: a literature review’. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimar et al

41. Correspondence to: ‘Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’

42. Response to: ‘Correspondence to: ‘Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’’ by Ma et al

43. Tapering antirheumatic drugs in a resource-poor setting: real-world evidence

44. Response to: ‘Tapering antirheumatic drugs in a resource-poor setting: real-world evidence’ by Haroon et al

45. Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica

46. Public/private partnerships, at what price?

47. Correction: Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis

PDF

ISSUE INFORMATION